Form 4: BridgeBio CAO Sells Shares Under Pre-Arranged Plan

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock at $66 per share under a Rule 10b5-1 sales plan.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), reported a sale of common stock.
• The transaction involved the disposition of 2,000 shares of common stock.
• The shares were sold at a price of $66 per share.
• Following this transaction, Apuli beneficially owns 121,945 shares of common stock.
• The sale was executed on February 26, 2026, pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading, and the sale price of $66 per share is notable.

Positives

• The sale was executed at a price of $66 per share, which could be considered a favorable price for the seller.
• The transaction was conducted under a pre-arranged Rule 10b5-1 sales plan, indicating a planned and transparent disposition of shares rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by investors as a reduction in insider confidence, though this is often mitigated by the pre-planned nature.
• The Chief Accounting Officer reduced her direct beneficial ownership by 2,000 shares.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general perception of insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that Rule 10b5-1 plans are a standard mechanism used by corporate insiders to sell company stock in a pre-scheduled manner, helping to avoid accusations of trading on material non-public information. Such plans are common across the biotechnology and pharmaceutical industries for executive compensation and diversification.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, potentially viewed neutrally given the 10b5-1 plan, but could be a slight negative signal if not understood in context.

Key Dates

Recommendation

The sale by the Chief Accounting Officer, Maricel Apuli, of 2,000 shares at $66 per share was conducted under a pre-arranged Rule 10b5-1 plan. This type of transaction is generally considered routine for executive compensation and diversification, and the relatively small volume compared to total holdings (121,945 shares remaining) does not suggest a significant change in management's outlook or warrant a strong directional recommendation. Therefore, a 'hold' recommendation is appropriate as this event alone is unlikely to be a major catalyst for the stock price.

Keywords

BridgeBio Pharma, BBIO, Insider Sale, Form 4, Maricel Apuli, Chief Accounting Officer, 10b5-1 Plan, Stock Transaction